Diabetes and obesity are lifestyle conditions that can lead to serious health problems. Obesity can increase the risk of ...

Obesity is a chronic health condition that can lead to the development of other conditions, such as type 2 diabetes and heart disease. The Centers for Disease Control and Prevention (CDC ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

New research shows adolescents also are less likely to develop type 2 diabetes after gastric bypass and sleeve gastrectomy ...

SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

Two thirds were women. The majority were aged 20-30 years (49.45%) or 31-40 years (27.47%). Overall, 73.63% reported having ...

Magnesium is an essential mineral with many benefits, such as supporting heart health, reducing inflammation, and maintaining ...

MASLD diagnosis was associated with an increased risk for youth-onset type 2 diabetes among pediatric patients with obesity.

Novo Nordisk’s drug helped reduce knee pain in osteoarthritis patients with obesity. Meanwhile, the Change Healthcare breach ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

AstraZeneca Plc said its experimental obesity pill was well-tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...